Get the Stockscreener App
6.23
0.32%
-0.02
After Hours:
6.22
-0.01
-0.16%
Minerva Neurosciences Inc stock is traded at $6.23, with a volume of 87,907.
It is down -0.32% in the last 24 hours and up +19.12% over the past month.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
See More
Previous Close:
$6.25
Open:
$6.31
24h Volume:
87,907
Relative Volume:
0.36
Market Cap:
$273.14M
Revenue:
-
Net Income/Loss:
$-293.42M
P/E Ratio:
-0.2324
EPS:
-26.8031
Net Cash Flow:
$-13.51M
1W Performance:
-2.50%
1M Performance:
+19.12%
6M Performance:
+71.15%
1Y Performance:
+286.96%
1-Day Range:
$6.02
$6.325
1-Week Range:
$5.88
$6.595
52-Week Range:
$1.30
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
6.23 | 274.01M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citizens | Mkt Outperform |
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences, Inc. 1Q 2026: Revenue $0 Net loss $(125.4M), EPS $(2.86) — 10-Q Summary - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Minerva Neurosciences (NERV) posts large Q1 2026 non-cash loss but keeps cash runway - Stock Titan
Phase 3 roluperidone trial and larger Q1 loss at Minerva (NERV) - Stock Titan
Minerva Neurosciences: Q1 Earnings Snapshot - marketscreener.com
No approved drug targets these schizophrenia symptoms; Phase 3 starts - Stock Titan
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update - MarketBeat
Minerva launched with new outperform at Citizens on schizophrenia candidate - MSN
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69 - MSN
Minerva Neurosciences | 8-K: Current report - Moomoo
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Officer liability and pay votes at Minerva Neurosciences (NASDAQ: NERV) 2026 meeting - Stock Titan
NERV (Minerva Neurosciences Inc) posts wider than expected Q4 2025 loss yet shares rise 5.28 percent on bullish investor sentiment.ADR - UBND thành phố Hải Phòng
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) officer James O’Connor files Form 3 - Stock Titan
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com South Africa
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest - MarketBeat
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
Minerva Neurosciences sets June 2026 date for annual stockholder meeting By Investing.com - Investing.com Australia
Minerva Neurosciences sets June 2026 date for annual stockholder meeting - Investing.com
Minerva Neurosciences sets June 3, 2026 annual meeting; stockholder notice deadlines announced - TradingView
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan
Ideas Watch: Is Minerva Neurosciences Inc stock a hidden gemPortfolio Gains Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - Investing.com
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):